HydroxyTyrosol / Vim Cancer Research Results

HT, HydroxyTyrosol: Click to Expand ⟱
Features:

Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.
Primary mechanisms (conceptual rank):
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).
PK / bioavailability: well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).
Clinical evidence status: strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.

Hydroxytyrosol is mostly only available from olive oil and leaves, but is available as a common supplement.
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).
Hydroxytyrosol is potent against CSC phenotypes.

Mechanisms:
-Blocks EMT, reducing transition into CSC-like states
-Inhibits Notch signaling
-Reduces CD44+ / CD24– CSC markers
-Inhibits hypoxia-driven stemness (HIF-1α suppression)

Hydroxytyrosol is especially active in:
-Breast CSCs
-Melanoma CSC-like cells
-Gastric CSC models

Hydroxytyrosol (HT) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS tone / lipid peroxidation ↓ (low–mod dose); ↑ (high concentration only) ↓ P→R Antioxidant; membrane protection Catechol scavenger; at higher concentrations may induce pro-oxidant stress in tumors (model-dependent).
2 NRF2 axis ↑ (context-dependent) ↑ R→G Endogenous antioxidant induction ↑ HO-1/NQO1; protective in normal tissues; could support tumor stress resistance (context-dependent).
3 NF-κB / COX-2 inflammation ↓ ↓ R→G Anti-inflammatory Reduces pro-tumor inflammatory signaling; consistent with Mediterranean diet data.
4 Mitochondrial function ↔ / ↓ proliferation (model-dependent) ↑ (protective) R→G Bioenergetic stabilization Reported support of mitochondrial integrity in normal cells; may impair cancer cell proliferation via metabolic stress.
5 Apoptosis (caspase activation) ↑ (high concentration only) ↔ / ↓ R→G Pro-apoptotic in select tumors Observed at supra-physiologic exposures in vitro.
6 Ferroptosis axis ↓ (anti-lipid-ROS bias) ↓ P→R Inhibits lipid oxidation Strong antioxidant property may counter ferroptotic strategies (context-dependent).
7 Clinical Translation Constraint — — — Exposure limitations Rapid metabolism; plasma free HT lower than many in-vitro doses; best considered dietary adjunct.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 EMT (Epithelial–Mesenchymal Transition) ↓ (model-/dose-dependent) ↔ R→G Reduces EMT-associated transcription (e.g., Snail, Twist) Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.
2 CSC markers (CD44+/CD24–) ↓ (model-dependent) ↔ G Reduces stemness-associated phenotype Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.
3 Notch signaling ↓ (model-dependent) ↔ R→G Stemness pathway inhibition Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.
4 HIF-1α / hypoxia-driven stemness ↓ (preclinical) ↔ R→G Suppresses hypoxia adaptation Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.
5 Tumor-type specificity Breast, Melanoma, Gastric (preclinical) — — CSC-like cell sensitivity Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr


Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / neuronal membrane protection ↓ P Neuroprotective antioxidant Protects against oxidative membrane injury; aligns with AD oxidative stress hypothesis.
2 NRF2 activation ↑ R→G Endogenous antioxidant upregulation Supports neuronal resilience under oxidative stress.
3 Neuroinflammation (NF-κB) ↓ R→G Microglial modulation Reduces pro-inflammatory cytokines in models.
4 Mitochondrial integrity ↑ R→G Bioenergetic stabilization Improves mitochondrial function in neuronal models; may reduce apoptotic susceptibility.
5 Aβ toxicity modulation ↓ (preclinical) G Reduces amyloid-induced oxidative injury Animal/cell evidence; limited direct human AD trials.
6 Clinical Translation Constraint — — Dietary-level evidence Human data strongest for Mediterranean diet patterns; isolated HT supplementation lacks large AD RCTs.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
Vim, Vimentin: Click to Expand ⟱
Source:
Type:
Vimentin, a major constituent of the intermediate filament family of proteins, is ubiquitously expressed in normal mesenchymal cells and is known to maintain cellular integrity and provide resistance against stress. Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.

In many epithelial-derived tumors (carcinomas), elevated Vimentin expression is often observed in cancer cells that have undergone EMT. This upregulation is characteristic of a shift toward a mesenchymal state, which is associated with reduced cell–cell adhesion and increased motility. Vimentin expression is also noted in the tumor stroma, reflecting the presence and activation of mesenchymal cells such as cancer-associated fibroblasts (CAFs). This dual expression can contribute to the remodeling of the tumor microenvironment.
The degree of Vimentin expression may vary depending on the tumor type, grade, and stage. More aggressive and advanced tumors tend to show higher levels of Vimentin expression.

High Vimentin expression has been correlated with poor clinical outcomes in several cancers, including breast, colorectal, prostate, and lung cancers.
Elevated Vimentin levels are typically associated with higher tumor grade, increased invasiveness, enhanced metastatic potential, and a greater risk of recurrence.
As a component of the EMT signature, high Vimentin expression can serve as an indicator of a more aggressive tumor phenotype and is often associated with reduced overall survival.
- vimentin up-regulation is often used as a marker of EMT in cancer



Scientific Papers found: Click to Expand⟱
4632- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, SUM159
CSCs↓, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, Wnt↓, p‑LRP6↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, SMAD2↓, SMAD3↓, TGF-β↓,
4636- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/ß-catenin and TGFß signaling
- in-vitro, BC, SUM159 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, BC, BT549
Wnt↓, β-catenin/ZEB1↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, TGF-β↓, CSCs↓, TumCMig↓, chemoP↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 2,   LRP6↓, 2,   p‑LRP6↓, 1,   Wnt↓, 2,  

Migration ⓘ

Slug↓, 2,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 2,   TGF-β↓, 2,   TumCI↓, 1,   TumCMig↓, 2,   Vim↓, 2,   Zeb1↓, 2,   β-catenin/ZEB1↓, 2,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 17

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Vim, Vimentin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:376  Target#:336  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page